Login
MANNKIND CORP logo

MANNKIND CORP

mannkindcorp.com

What Do They Do?

Develops and commercializes inhaled medicines, injectable treatments and insulin-delivery devices for people with diabetes, heart or kidney disease, and pulmonary hypertension.

How Do They Make Money?

MannKind earns product revenue from sales of Afrezza, Furoscix and V-Go to wholesalers and specialty pharmacies, and from Tyvaso DPI supplies delivered to United Therapeutics. Collaboration arrangements bring in revenue for research and development services, while royalties are based on United Therapeutics' Tyvaso DPI net sales.

revenue
SegmentShareRevenue
Product Revenue
Sold outright

62%
FY2022: 81%
Services
1.2%
FY2022: 3.1%
Royalties
Licensed

37%
FY2022: 16%

Who Are Their Customers?

Commercial products are sold through wholesale distributors, specialty and retail pharmacies, and durable medical equipment suppliers. MannKind commercializes Afrezza, Furoscix and V-Go itself in the U.S., works with regional partners outside it, and United Therapeutics commercializes Tyvaso DPI.

Customers above 10% of revenue, FY2025
of revenue from three customers (11%, 11%, 8%)
FY2023: 46% from three customers

Do Revenues Turn Into Profits?

Yes. It kept 2 cents of every revenue dollar as net income in FY2025 and turned 4 cents into free cash flow.

Operating income, FY2025
11% of revenue
▼ −47% vs FY2024 ($72.6M, 25%)
Net income, FY2025
2% of revenue
▼ −79% vs FY2024 ($27.6M, 10%)
Free cash flow, FY2025
4% of revenue
▼ −58% vs FY2024 ($32.8M, 11%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +24%
vs $82.1M in Q3 FY2025
Net income
▼ Turned to a loss
vs $8M in Q3 FY2025
Product Revenue share of revenue vs 58.8% in Q3 FY2025

Growing. Revenue grew 4.6x in 4 years, from $75.4M in FY2021 to $349M in FY2025, about 47% a year.

Furoscix joins the portfolio MannKind's commercial portfolio moved beyond Afrezza and V-Go to include Furoscix, a furosemide treatment delivered through an on-body infusor.

Afrezza in India The older report described Cipla as conducting a study toward an Indian regulatory submission; the latest says MannKind sent Cipla an initial Afrezza shipment for an India launch.

Revenue over time
Product Revenue Services Royalties
$500M$250M$0

Who Do They Compete With?

Competes with Eli Lilly and, Novo Nordisk, Sanofi, AstraZeneca, Abbott Laboratories, Amgen, Bayer, Bioheart, Boston Scientific, Boehringer Ingelheim, Corstasis, GlaxoSmithKline, Johnson & Johnson, Merck, Medtronic, Novartis, Pfizer, Roche, Sarfez Pharmaceuticals, and Servier Pharmaceuticals

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support